

Article

Asymmetric Construction of All-Carbon Quaternary Stereocenters by Chiral-Auxiliary-Mediated Claisen Rearrangement and Total Synthesis of (+)-Bakuchiol

Ken-ichi Takao *, Shu Sakamoto, Marianne Ayaka Touati, Yusuke Kusakawa and Kin-ichi Tadano *

Department of Applied Chemistry, Keio University, Hiyoshi, Kohoku-ku, Yokohama 223-8522, Japan

* Authors to whom correspondence should be addressed; E-Mails: takao@aplc.keio.ac.jp (K.T.); tadano@aplc.keio.ac.jp (K.T.); Tel.: +81-45-566-1570 (Ken-ichi Takao); Fax: +81-45-566-1551 (Ken-ichi Takao).

Received: 9 October 2012; in revised form: 23 October 2012 / Accepted: 2 November 2012 / Published: 8 November 2012

Abstract: An asymmetric Claisen rearrangement using Oppolzer's camphorsultam was developed. Under thermal conditions, a geraniol-derived substrate underwent the rearrangement with good stereoselectivity. The absolute configuration of the newly formed all-carbon quaternary stereocenter was confirmed by the total synthesis of (+)-bakuchiol from the rearrangement product.


Keywords: Claisen rearrangement; chiral auxiliary; camphorsultam; quaternary stereocenter; total synthesis

1. Introduction

The construction of asymmetric quaternary stereocenters remains a challenge in organic synthesis [1–3]. All-carbon quaternary stereocenters are found in a wide range of complex natural products which share such a structural motif, including (+)-hyperforin (**1**) [4], (+)-perforatumone (**2**) [5,6], (+)-vibsanin A (**3**) [7], and (+)-bakuchiol (**4**) [8–13] (Figure 1). To achieve the total synthesis of these natural products, a practical method for constructing the quaternary stereocenter is necessary. We focused on the Claisen rearrangement as an approach to this challenge. The [3,3]-sigmatropic rearrangement of allyl vinyl ethers, that is, the Claisen rearrangement, is among the most useful tools for forming carbon-carbon bonds and its asymmetric variants have been well studied [14,15]. Herein, we describe a new method for

the asymmetric construction of an all-carbon quaternary stereocenter by a chiral-auxiliary-mediated Claisen rearrangement.


Figure 1. Structures of (+)-hyperforin, (+)-perforatumone, (+)-vibsanin A, and (+)-bakuchiol.



2. Results and Discussion

Oppolzer's camphorsultam was used as a chiral auxiliary for the asymmetric Claisen rearrangement. We designed a novel substrate, a β -(allyloxy)acrylate derivative bearing the camphorsultam. Accordingly, *N*-propioloyl camphorsultam **5** was prepared by our previously reported procedure (Scheme 1) [16–18]. The oxy-Michael addition of geraniol to **5** in the presence of a catalytic amount of tributylphosphine gave adduct **6** with complete *E*-stereoselectivity [19]. A toluene solution of **6** in the presence of butylated hydroxytoluene (BHT) used as a polymerization inhibitor was heated in a sealed tube at 140 °C to provide mainly the (2*R*,3*S*)-isomer **7a** as the rearrangement product in 72% yield, securing the two contiguous stereocenters including the quaternary carbon. The minor (2*S*,3*R*)-isomer **7b** (8%) was easily separated from **7a** by column chromatography on silica gel [20].


Scheme 1. Claisen rearrangement of geraniol-derived substrate **6**.



By using a similar procedure, nerol-derived substrate **8** was prepared from **5** and nerol (Scheme 2). The Claisen rearrangement of **8** afforded (2*R*,3*R*)-isomer **7c** and (2*S*,3*S*)-isomer **7d**, accompanied by a


small amount of **7a** and **7b**, respectively. Compared with the case of **6**, however, lower stereoselectivity was observed. Brief exposure of **7a** to base caused epimerization at C-2 to produce isomer **7d**, indicating that the quaternary stereocenter in nerol-derived rearrangement product **7c** has stereochemistry opposite to that in **7a**.

Scheme 2. Claisen rearrangement of nerol-derived substrate **8**.




The stereochemistry of the newly formed quaternary stereocenter (C-3) in **7a** was determined by the total synthesis of (+)-bakuchiol (**4**), a major component of the Indian medicinal plant *Psoralea corylifolia* Linn [8]. Base hydrolysis of **7a** followed by decarboxylation provided enantiomerically pure aldehyde **9**, and the chiral auxiliary was recovered (Scheme 3). Treatment of **9** with *p*-MeOC₆H₄MgBr afforded alcohol **10**, which was subjected to dehydration using phosphoryl chloride to afford bakuchiol methyl ether **11** [21]. By comparing the optical rotation of synthetic **11** $\{[\alpha]_D^{25} + 28.4 (c 0.855, \text{CHCl}_3)\}$ with that reported for the authentic sample $\{\text{lit. } [\alpha]_D^{29} + 31.2 (c 1.45, \text{CHCl}_3)\}$ [9], the absolute configuration of the quaternary stereocenter in **7a** was assigned as (*S*). According to a known procedure [22], demethylation of **11** finally provided (+)-bakuchiol (**4**), which was identical to the natural product in all respects.

Scheme 3. Determination of the stereochemistry at C-3 in **7a** and total synthesis of (+)-bakuchiol.




To determine the configuration at C-2, rearrangement product **7a** was heated at 160 °C (Scheme 4). The intramolecular carbonyl–ene reaction proceeded to provide cyclized **12a** as a mixture of four diastereomers (dr = 3:2:2:1). Similarly, **7c** was converted into **12c** (dr = 9:8:2:1). Through NOE experiments on the isolated major diastereomers **12aa** and **12ca**, the stereochemistry at the C-2 in **7a** and **7c** was assigned as (*R*). Therefore, the configurations of all stereocenters in the rearrangement products **7a–d** were unambiguously assigned.

Scheme 4. Determination of the stereochemistry at C-2 in **7a** and **7c**.




To expand the scope of this reaction, (*E,E*)- β -(allyloxy)acrylate substrates **14** and **17** were synthesized by oxy-Michael addition of allylic alcohols **13** and **16** [23] to **5** (Scheme 5). In both cases, the Claisen rearrangements of **14** and **17** afforded (*2R,3S*)-isomers **15a** and **18a** preferentially, with good stereoselectivity in more than 70% yield, similarly to the reaction of **6**.

Scheme 5. Claisen rearrangements of **14** and **17**.




The vicinal stereocenters in **15a** and **18a** were assigned by chemical transformation (Scheme 6). Chemoselective reduction of **7a**, followed by acetylation of the resulting alcohol, provided acetate **19a**. The spectroscopic data (^1H - and ^{13}C -NMR) of **19a** were distinguishable from those of **19b** derived from **7b**. On the other hand, **15a** was converted into acetate **20a**. Desilylation of **20a**, oxidation of the resulting alcohol to aldehyde, and subsequent Wittig olefination afforded **19a** whose NMR spectra matched those of **19a** derived from **7a**. Compound **18a** was also converted into **19a** via acetate **21a**. Therefore, the configuration of the vicinal stereocenters at the C-2 and C-3 in **15a** and **18a** coincides with that of **7a**.

Scheme 6. Determination of the stereochemistry at C-2 and C-3 in **15a** and **18a**.



The stereochemical outcomes observed in the reactions of **6**, **14**, **17**, and **8** can be explained by the transition states depicted in Scheme 7.

Scheme 7. Plausible transition states for the Claisen rearrangements of **6**, **14**, **17**, and **8**.



In the more favorable conformation of **6**, **14**, and **17**, the carbonyl group is directed *anti* to the sulfonyl group and adopts an *s-cis* conformation with respect to the α,β -unsaturated bond [24]. The rearrangement proceeds predominantly from the *C α -Re*-face through a six-membered chair-like transition state to avoid the steric repulsion that would be encountered along the *C α -Si*-face path. As a result, **7a**, **15a**, and **18a** were obtained as the major isomers. Also nerol-derived substrate **8** rearranges through the same *C α -Re*-face path to produce **7c**. In this case, the bulky homoprenyl group takes an axial orientation, which causes a decrease of the stereoselectivity.

3. Experimental

General

Melting points are uncorrected. Specific rotations were measured in a 100 mm cell. $^1\text{H-NMR}$ spectra were recorded at 500 MHz with tetramethylsilane as an internal standard on a JEOL JNM-ECA500 spectrometer. $^{13}\text{C-NMR}$ spectra were recorded at 125 MHz. All spectra were recorded in CDCl_3 . High-resolution mass spectra (HRMS) were measured in EI mode (70 eV) on a JEOL JMS-GCmate spectrometer. Thin-layer chromatography (TLC) was performed on Merck Kieselgel 60 F_{254} plates. The crude reaction mixtures and extracted materials were purified by column chromatography on Silica gel 60 (Merck) or Wakogel C-300 (Wako). Unless otherwise noted, reactions were carried out at room temperature. Combined organic extracts were dried over anhydrous Na_2SO_4 . Solvents were removed from the reaction mixture and the combined organic extracts by concentration under reduced pressure using an evaporator with bath at 35–45 °C.

(2*R*)-*N*-{(*E*)-3-[(*2E*)-3,7-Dimethylocta-2,6-dien-1-yl]oxy}acryloyl}bornane-10,2-sultam (**6**). The following reaction was carried out under Ar. To a cooled (0 °C) stirred solution of **5** (302 mg, 1.13 mmol) in CH_2Cl_2 (11 mL) were added geraniol (218 μL , 1.24 mmol) and *n*- Bu_3P (42 μL , 0.17 mmol). The mixture was stirred at 0 °C for 30 min, diluted with H_2O (20 mL), and extracted with CH_2Cl_2 (10 mL \times 3). The combined extracts were washed with saturated brine (20 mL), dried and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel (EtOAc/hexane, 1:30) to provide 368 mg (77%) of **6** as a colorless oil: TLC R_f 0.54 (EtOAc/hexane, 1:3); $[\alpha]_D^{19}$ –59.2 (*c* 1.19, CHCl_3); IR (neat) 2962, 2885, 1678, 1608 cm^{-1} ; $^1\text{H-NMR}$ (500 MHz): δ 0.97 (s, 3H), 1.18 (s, 3H), 1.34–1.45 (m, 2H), 1.60 (br s, 3H), 1.68 (br s, 3H), 1.71 (br s, 3H), 1.86–1.91 (m, 3H), 2.05–2.17 (m, 6H), 3.43 (d, 1H, $J = 13.8$ Hz), 3.48 (d, 1H, $J = 13.8$ Hz), 3.91 (dd, 1H, $J = 4.9, 7.7$ Hz), 4.45 (d, 2H, $J = 6.9$ Hz), 5.08 (m, 1H), 5.37 (qt, 1H, $J = 1.0, 6.9$ Hz), 5.97 (d, 1H, $J = 12.1$ Hz), 7.70 (d, 1H, $J = 12.1$ Hz); $^{13}\text{C-NMR}$ (125 MHz) δ 16.6, 17.6, 19.9, 20.7, 25.6, 26.1, 26.5, 32.7, 38.5, 39.4, 44.6, 47.7, 48.2, 53.0, 65.0, 68.1, 97.0, 117.5, 123.5, 131.9, 143.4, 163.3, 164.9; HRMS calcd for $\text{C}_{23}\text{H}_{35}\text{NO}_4\text{S}$ (M^+) m/z 421.2287, found 421.2286.

(2*R*)-*N*-[(2*R*,3*S*)-2-Formyl-3,7-dimethyl-3-vinyloct-6-enoyl]bornane-10,2-sultam (**7a**) and (2*R*)-*N*-[(2*S*,3*R*)]-isomer (**7b**). A solution of **6** (400 mg, 949 μmol) and BHT (10.5 mg, 47.5 μmol) in toluene (50 mL) was stirred at 140 °C for 65 h in a sealed tube and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel (EtOAc/hexane, 1:30) to provide 289 mg (72%) of **7a** and 30.9 mg (8%) of **7b**. Compound **7a** was obtained as white crystals: mp 84–87 °C;

TLC R_f 0.49 (EtOAc/hexane, 1:3); $[\alpha]_D^{21}$ -77.9 (c 2.55, CHCl₃); IR (neat) 2960, 2925, 1730, 1680 cm⁻¹; ¹H-NMR (500 MHz) δ 0.98 (s, 3H), 1.15 (s, 3H), 1.26 (s, 3H), 1.37–1.46 (m, 3H), 1.56 (br s, 3H), 1.65 (br s, 3H), 1.67 (m, 1H), 1.87–1.96 (m, 5H), 2.06–2.15 (m, 2H), 3.44 (d, 1H, J = 13.8 Hz), 3.51 (d, 1H, J = 13.8 Hz), 3.96 (dd, 1H, J = 5.2, 7.4 Hz), 4.01 (d, 1H, J = 2.3 Hz), 5.02 (m, 1H), 5.07 (d, 1H, J = 17.4 Hz), 5.21 (d, 1H, J = 10.6 Hz), 5.92 (dd, 1H, J = 10.6, 17.4 Hz), 9.61 (d, 1H, J = 2.3 Hz); ¹³C-NMR (125 MHz) δ 17.6, 19.7, 19.9, 20.7, 22.2, 25.6, 26.4, 32.9, 38.5 (2C), 44.8, 45.5, 47.7, 48.1, 53.2, 65.4 (2C), 115.2, 123.7, 131.9, 142.3, 167.5, 197.3; HRMS calcd for C₂₃H₃₅NO₄S (M⁺) m/z 421.2287, found 421.2283. Compound **7b** was obtained as white crystals: mp 81–87 °C; TLC R_f 0.61 (EtOAc/hexane, 1:3); $[\alpha]_D^{17}$ +38.5 (c 0.965, CHCl₃); IR (neat) 2960, 2925, 1730, 1700 cm⁻¹; ¹H-NMR (500 MHz) δ 0.95 (s, 3H), 1.10 (s, 3H), 1.31 (s, 3H), 1.34–1.43 (m, 2H), 1.54–1.68 (m, 2H), 1.56 (br s, 3H), 1.65 (br s, 3H), 1.88–1.93 (m, 5H), 2.08 (dd, 1H, J = 7.8, 13.9 Hz), 2.28 (m, 1H), 3.43 (d, 1H, J = 13.7 Hz), 3.48 (d, 1H, J = 13.7 Hz), 3.90 (dd, 1H, J = 4.9, 7.8 Hz), 4.21 (d, 1H, J = 0.9 Hz), 5.04 (m, 1H), 5.12 (dd, 1H, J = 0.6, 17.5 Hz), 5.26 (dd, 1H, J = 0.6, 10.8 Hz), 6.01 (dd, 1H, J = 10.8, 17.5 Hz), 9.60 (d, 1H, J = 0.9 Hz); ¹³C-NMR (125 MHz) δ 17.6, 19.3, 19.9, 20.4, 22.2, 25.7, 26.5, 32.7, 38.2, 38.9, 42.9, 44.5, 47.8, 48.2, 53.1, 65.1, 65.3, 115.1, 124.0, 131.7, 143.5, 166.3, 197.7; HRMS calcd for C₂₃H₃₅NO₄S (M⁺) m/z 421.2287, found 421.2281.

(2*R*)-*N*-{(*E*)-3-[(*2Z*)-3,7-Dimethylocta-2,6-dien-1-yl]oxy]acryloyl}bornane-10,2-sultam (**8**). As described for the preparation of **6**, compound **5** (210 mg, 785 μ mol) and nerol (155 μ L, 882 μ mol) were treated with *n*-Bu₃P (32 μ L, 0.12 mmol) in CH₂Cl₂ (8 mL) to provide 234 mg (71%) of **8** as white crystals: mp 62–64 °C; TLC R_f 0.52 (EtOAc/hexane, 1:3); $[\alpha]_D^{26}$ -71.0 (c 1.22, CHCl₃); IR (neat) 2964, 2884, 1677, 1607 cm⁻¹; ¹H-NMR (500 MHz) δ 0.97 (s, 3H), 1.18 (s, 3H), 1.34–1.45 (m, 2H), 1.60 (br s, 3H), 1.69 (br s, 3H), 1.78 (br s, 3H), 1.87–1.91 (m, 3H), 2.05–2.17 (m, 6H), 3.43 (d, 1H, J = 13.7 Hz), 3.48 (d, 1H, J = 13.7 Hz), 3.91 (dd, 1H, J = 4.9, 7.8 Hz), 4.41 (d, 2H, J = 7.0 Hz), 5.08 (m, 1H), 5.39 (t, 1H, J = 7.0 Hz), 5.96 (d, 1H, J = 12.0 Hz), 7.69 (d, 1H, J = 12.0 Hz); ¹³C-NMR (125 MHz) δ 17.6, 19.9, 20.8, 23.5, 25.7, 26.5 (2C), 32.3, 32.8, 38.6, 44.7, 47.8, 48.2, 53.1, 65.0, 67.9, 97.0, 118.5, 123.3, 132.5, 143.8, 163.4, 165.0; HRMS calcd for C₂₃H₃₅NO₄S (M⁺) m/z 421.2287, found 421.2287.

(2*R*)-*N*-[(2*R*,3*R*)-2-Formyl-3,7-dimethyl-3-vinyloct-6-enoyl]bornane-10,2-sultam (**7c**) and (2*R*)-*N*-[(2*S*,3*S*)]-isomer (**7d**). As described for the preparation of **7a** and **7b** from **6**, a solution of **8** (223 mg, 529 μ mol) and BHT (5.8 mg, 26 μ mol) in toluene (27 mL) was heated at 140 °C for 26 h to provide 147 mg (66%) of a mixture of **7c** and **7a** (**7c**/**7a** = 19:1) and 25.0 mg (11%) of a mixture of **7d** and **7b** (**7d**/**7b** = 10:1), and 27.9 mg (13%) of **8** was recovered. A mixture of **7c** and **7a** (**7c**/**7a** = 19:1) was obtained as a colorless oil: TLC R_f 0.49 (EtOAc/hexane, 1:3); $[\alpha]_D^{28}$ -82.4 (c 1.26, CHCl₃); IR (neat) 2965, 2930, 1727, 1684 cm⁻¹; ¹H-NMR (500 MHz) for **7c** δ 0.97 (s, 3H), 1.16 (s, 3H), 1.26 (s, 3H), 1.34–1.49 (m, 3H), 1.55 (br s, 3H), 1.65 (br s, 3H), 1.68 (m, 1H), 1.84–1.93 (m, 5H), 2.03–2.09 (m, 2H), 3.43 (d, 1H, J = 13.8 Hz), 3.50 (d, 1H, J = 13.8 Hz), 3.89 (d, 1H, J = 3.5 Hz), 3.92 (dd, 1H, J = 5.5, 7.4 Hz), 5.02 (m, 1H), 5.02 (dd, 1H, J = 1.0, 17.4 Hz), 5.14 (dd, 1H, J = 1.0, 10.9 Hz), 6.02 (dd, 1H, J = 10.9, 17.4 Hz), 9.66 (d, 1H, J = 3.5 Hz); ¹³C-NMR (125 MHz) for **7c** δ 17.6, 18.9, 19.9, 20.7, 22.2, 25.6, 26.4, 33.0, 38.2, 39.5, 44.7, 45.8, 47.7, 48.1, 53.3, 65.4, 65.5, 115.2, 123.7, 131.8, 141.7, 167.9, 197.8; HRMS calcd for C₂₃H₃₅NO₄S (M⁺) m/z 421.2287, found 421.2289. A mixture of **7d** and **7b** (**7d**/**7b** = 10:1) was obtained as a colorless oil: TLC R_f 0.61 (EtOAc/hexane, 1:3); $[\alpha]_D^{26}$ +2.9

(*c* 1.25, CHCl₃); IR (neat) 2964, 2924, 1728, 1697 cm⁻¹; ¹H-NMR (500 MHz) for **7d** δ 0.95 (s, 3H), 1.09 (s, 3H), 1.31–1.42 (m, 2H), 1.34 (s, 3H), 1.57 (m, 1H), 1.57 (br s, 3H), 1.65 (br s, 3H), 1.76 (m, 1H), 1.87–1.95 (m, 5H), 2.07 (dd, 1H, *J* = 7.9, 14.0 Hz), 2.25 (m, 1H), 3.43 (d, 1H, *J* = 13.9 Hz), 3.49 (d, 1H, *J* = 13.9 Hz), 3.90 (dd, 1H, *J* = 4.9, 7.9 Hz), 4.19 (d, 1H, *J* = 1.1 Hz), 5.06 (m, 1H), 5.06 (d, 1H, *J* = 17.2 Hz), 5.17 (d, 1H, *J* = 10.9 Hz), 6.14 (dd, 1H, *J* = 10.9, 17.2 Hz), 9.68 (d, 1H, *J* = 1.1 Hz); ¹³C-NMR (125 MHz) for **7d** δ 17.6, 19.9, 20.4, 21.2, 23.4, 25.6, 26.4, 32.7, 38.2, 39.1, 43.3, 44.5, 47.7, 48.2, 53.1, 65.3, 66.2, 114.7, 123.9, 131.7, 142.6, 166.3, 197.0; HRMS calcd for C₂₃H₃₅NO₄S (M⁺) *m/z* 421.2287, found 421.2288.

Epimerization of 7a. To a stirred solution of **7a** (7.9 mg, 19 μmol) in CH₂Cl₂ (1 mL) was added DBU (3.6 μL, 24 μmol). The mixture was stirred at room temperature for 45 min, diluted with 1 M aqueous HCl (1 mL), and extracted with CH₂Cl₂ (2 mL × 3). The combined extracts were washed with saturated brine (1 mL), dried and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel (EtOAc/hexane, 1:25) to provide 1.1 mg (14%) of **7d** and 6.7 mg (85%) of **7a** was recovered.

(1*R*S,3*R*)-1-(4-Methoxyphenyl)-3,7-dimethyl-3-vinyloct-6-enol (10). To a cooled (0 °C) stirred solution of **7a** (233 mg, 553 μmol) in THF/H₂O (1:1, 5 mL) was added 1.00 M aqueous KOH (1.11 mL, 1.11 mmol). The mixture was stirred at room temperature for 24 h, quenched with saturated aqueous NH₄Cl (2 mL), diluted with H₂O (2 mL), and extracted with Et₂O (5 mL × 3). The combined extracts were washed with saturated brine (15 mL) and dried to provide a solution of aldehyde **9** in Et₂O, which was used in the next step without further evaporation and purification.

The following reaction was carried out under Ar. To a cooled (0 °C) stirred solution of aldehyde **9** in Et₂O obtained above was added 4-methoxyphenylmagnesium bromide (1.50 M solution in Et₂O, total 6.27 mL, total 9.41 mmol) in ten times over a period of 2 h. The mixture was quenched with saturated aqueous NH₄Cl (30 mL), diluted H₂O (10 mL), and extracted with CH₂Cl₂ (40 mL × 3). The combined extracts were dried and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel (EtOAc/hexane, 1:40) to provide 86.7 mg (55%) of **10** and 114 mg (96%) of camphorsultam. Compound **10** (dr = 1:1) was obtained as a colorless oil: TLC *R_f* 0.61 (EtOAc/hexane, 1:3); IR (neat) 3442, 2965, 2924, 1612, 1512 cm⁻¹; ¹H-NMR (500 MHz) δ 1.10 (s, 3H × 1/2), 1.11 (s, 3H × 1/2), 1.34 (t, 2H × 1/2, *J* = 8.5 Hz), 1.40–1.43 (m, 2H × 1/2), 1.57 (br s, 3H × 1/2), 1.59 (br s, 3H × 1/2), 1.66 (br s, 3H × 1/2), 1.67 (br s, 3H × 1/2), 1.80–1.93 (m, 4H), 3.79 (s, 3H), 4.74 (dd, 1H × 1/2, *J* = 2.6, 8.6 Hz), 4.79 (dd, 1H × 1/2, *J* = 2.6, 9.3 Hz), 5.02 (dd, 1H × 1/2, *J* = 1.1, 17.7 Hz), 5.07 (dd, 1H × 1/2, *J* = 1.1, 10.8 Hz), 5.07 (m, 1H), 5.07 (dd, 1H × 1/2, *J* = 0.9, 17.7 Hz), 5.14 (dd, 1H × 1/2, *J* = 0.9, 10.8 Hz), 5.83 (dd, 1H × 1/2, *J* = 10.8, 17.7 Hz), 5.97 (dd, 1H × 1/2, *J* = 10.8, 17.7 Hz), 6.86 (d, 2H × 1/2, *J* = 8.8 Hz), 6.86 (d, 2H × 1/2, *J* = 8.6 Hz), 7.24 (d, 2H × 1/2, *J* = 8.8 Hz), 7.25 (d, 2H × 1/2, *J* = 8.6 Hz); ¹³C-NMR (125 MHz) δ 17.6, 21.3 (1/2C), 22.5 (1/2C), 22.7 (1/2C), 23.5 (1/2C), 25.7, 39.5, 40.5 (1/2C), 42.5 (1/2C), 50.3 (1/2C), 51.1 (1/2C), 55.3, 71.4 (1/2C), 71.5 (1/2C), 112.2 (1/2C), 112.9 (1/2C), 113.7, 113.8, 124.6 (1/2C), 124.8 (1/2C), 126.9 (2C), 131.2 (1/2C), 131.3 (1/2C), 137.7 (1/2C), 138.3 (1/2C), 147.4 (1/2C), 147.7 (1/2C), 158.8; HRMS calcd for C₁₉H₂₈O₂ (M⁺) *m/z* 288.2089, found 288.2090.

(1*E*,3*S*)-1-(4-Methoxyphenyl)-3,7-dimethyl-3-vinylocta-1,6-diene (**11**). The following reaction was carried out under Ar. To a stirred solution of **10** (22.5 mg, 78.0 μmol) in pyridine (1 mL) was added POCl_3 (8.6 μL , 95 μmol). The mixture was refluxed for 4 h, diluted with EtOAc (15 mL), and washed with H_2O (10 mL) and saturated brine (10 mL). The organic layer was dried and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel (EtOAc/hexane, 1:100) to provide 18.9 mg (90%) of **11** as a colorless oil: TLC R_f 0.80 (EtOAc/hexane, 1:3); $[\alpha]_D^{25} + 28.4$ (c 0.855, CHCl_3); IR (neat) 2966, 2916, 1609, 1511 cm^{-1} ; $^1\text{H-NMR}$ (500 MHz) δ 1.20 (s, 3H), 1.48–1.51 (m, 2H), 1.58 (br s, 3H), 1.67 (br s, 3H), 1.93–1.98 (m, 2H), 3.80 (s, 3H), 5.01 (dd, 1H, $J = 1.4, 17.5$ Hz), 5.03 (dd, 1H, $J = 1.4, 10.7$ Hz), 5.11 (m, 1H), 5.88 (dd, 1H, $J = 10.7, 17.5$ Hz), 6.06 (d, 1H, $J = 16.4$ Hz), 6.26 (d, 1H, $J = 16.4$ Hz), 6.83 (d, 2H, $J = 8.7$ Hz), 7.29 (d, 2H, $J = 8.7$ Hz); $^{13}\text{C-NMR}$ (125 MHz) δ 17.6, 23.2, 23.4, 25.7, 41.3, 42.5, 55.3, 111.8, 113.9 (2C), 124.8, 126.5, 127.1 (2C), 130.7, 131.3, 135.8, 146.0, 158.7; HRMS calcd for $\text{C}_{19}\text{H}_{26}\text{O}$ (M^+) m/z 270.1984, found 270.1983.

(+)-Bakuchiol (**4**). The following reaction was carried out under Ar. To a cooled (0 $^\circ\text{C}$) solution of **11** (30.2 mg, 112 μmol) in Et_2O (1 mL) was added MeMgI (0.500 M solution in Et_2O , 1.57 mL, 785 μmol). The solvent was removed under reduced pressure. The residue was heated at 180 $^\circ\text{C}$ for 15 min and cooled to room temperature. The mixture was quenched with 1 M aqueous HCl (2 mL), diluted with H_2O (2 mL), and extracted with CH_2Cl_2 (5 mL \times 3). The combined extracts were dried and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel (EtOAc/hexane, 1:60) to provide 26.1 mg (91%) of **4** as a pale yellow oil: TLC R_f 0.63 (EtOAc/hexane, 1:3); $[\alpha]_D^{29} + 25.6$ (c 0.795, CHCl_3); IR (neat) 3359, 2967, 2924, 1610, 1513 cm^{-1} ; $^1\text{H-NMR}$ (500 MHz) δ 1.19 (s, 3H), 1.47–1.51 (m, 2H), 1.58 (br s, 3H), 1.67 (br s, 3H), 1.93–1.97 (m, 2H), 4.85 (br, 1H, OH), 5.01 (dd, 1H, $J = 1.5, 17.4$ Hz), 5.03 (dd, 1H, $J = 1.5, 10.8$ Hz), 5.11 (m, 1H), 5.88 (dd, 1H, $J = 10.8, 17.4$ Hz), 6.05 (d, 1H, $J = 16.2$ Hz), 6.25 (d, 1H, $J = 16.2$ Hz), 6.76 (d, 2H, $J = 8.6$ Hz), 7.24 (d, 2H, $J = 8.6$ Hz); $^{13}\text{C-NMR}$ (125 MHz) δ 17.6, 23.2, 23.3, 25.7, 41.3, 42.5, 111.9, 115.3 (2C), 124.8, 126.4, 127.4 (2C), 130.9, 131.3, 135.9, 145.9, 154.6; HRMS calcd for $\text{C}_{18}\text{H}_{24}\text{O}$ (M^+) m/z 256.1827, found 256.1829.

(2*R*)-*N*-[(1*R*,2*S*,5*R*,6*R*)-6-Hydroxy-5-isopropenyl-2-methyl-2-vinylcyclohexanecarbonyl]bornane-10,2-sultam (**12aa**) and its diastereomers. A solution of **7a** (22.8 mg, 54.1 μmol) and BHT (a crystal) in toluene (6 mL) was stirred at 160 $^\circ\text{C}$ for 50 h in a sealed tube and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel (EtOAc/hexane, 1:15) to provide 4.9 mg (21%) of **12aa**, 3.2 mg (14%) of **12ab**, 3.3 mg (14%) of **12ac**, and 1.7 mg (7%) of **12ad**. Compound **12aa** was obtained as white crystals: mp 198–200 $^\circ\text{C}$; TLC R_f 0.43 (EtOAc/hexane, 1:2); $[\alpha]_D^{21} - 10.5$ (c 0.27, CHCl_3); IR (neat) 3520, 2960, 1695 cm^{-1} ; $^1\text{H-NMR}$ (500 MHz) δ 0.97 (s, 3H), 1.16 (s, 3H), 1.17 (s, 3H), 1.36–1.44 (m, 2H), 1.51–1.56 (m, 2H), 1.67–1.79 (m, 2H), 1.73 (br s, 3H), 1.86–1.92 (m, 3H), 2.02 (d, 1H, $J = 8.3$ Hz, OH), 2.08–2.15 (m, 3H), 2.99 (d, 1H, $J = 10.6$ Hz), 3.47 (d, 1H, $J = 13.9$ Hz), 3.53 (d, 1H, $J = 13.9$ Hz), 3.94 (dt, 1H, $J = 8.3, 10.6$ Hz), 4.00 (dd, 1H, $J = 5.1, 7.7$ Hz), 4.83 (s, 1H), 4.85 (s, 1H), 4.98 (dd, 1H, $J = 1.2, 17.5$ Hz), 5.12 (dd, 1H, $J = 1.2, 11.2$ Hz), 6.43 (dd, 1H, $J = 11.2, 17.5$ Hz); $^{13}\text{C-NMR}$ (125 MHz) δ 19.2, 20.0, 20.9, 26.4, 26.5, 27.8, 33.0, 38.7, 39.0, 42.5, 44.8, 47.6, 47.7, 53.6, 54.1, 60.7, 65.9, 70.3, 112.5, 113.1, 141.5, 146.2, 171.9; HRMS calcd for $\text{C}_{23}\text{H}_{35}\text{NO}_4\text{S}$ (M^+) m/z 421.2287, found 421.2291.

(2*R*)-*N*-[(1*R*,2*R*,5*R*,6*R*)-6-Hydroxy-5-isopropenyl-2-methyl-2-vinylcyclohexanecarbonyl]bornane-10,2-sultam (**12ca**) and its diastereomers. As described for the preparation of **12aa** and its diastereomers from **7a**, a solution of **7c** (23.5 mg, 55.7 μ mol) and BHT (a crystal) in toluene (6 mL) was heated at 160 °C for 40 h to provide 8.7 mg (37%) of **12ca**, 9.2 mg (39%) of a mixture of **12cb** and **12cc**, and 0.9 mg (4%) of **12cd**. Compound **12ca** was obtained as white crystals: TLC R_f 0.32 (EtOAc/hexane, 1:2); $^1\text{H-NMR}$ (500 MHz) δ 0.95 (s, 3H), 1.15 (s, 3H), 1.19 (s, 3H), 1.23–1.41 (m, 3H), 1.50–1.70 (m, 3H), 1.78 (br s, 3H), 1.81–1.96 (m, 3H), 2.02–2.06 (m, 3H), 2.10 (dt, 1H, $J = 5.0, 10.6$ Hz), 3.00 (d, 1H, $J = 10.5$ Hz), 3.45 (d, 1H, $J = 13.9$ Hz), 3.50 (d, 1H, $J = 13.9$ Hz), 3.95 (dd, 1H, $J = 5.2, 7.8$ Hz), 4.00 (q, 1H, $J = 10.5$ Hz), 4.85 (s, 1H), 4.86 (s, 1H), 4.90 (d, 1H, $J = 10.6$ Hz), 4.98 (d, 1H, $J = 17.5$ Hz), 6.00 (dd, 1H, $J = 10.6, 17.5$ Hz).

(2*R*)-*N*-{(*E*)-3-[(2*E*)-6-(*tert*-Butyldiphenysilyloxy)-3-methylhex-2-en-1-yl]oxy}acryloyl}bornane-10,2-sultam (**14**). As described for the preparation of **6**, compound **5** (109 mg, 408 μ mol) and **13** (165 mg, 448 μ mol) were treated with *n*-Bu₃P (15 μ L, 61 μ mol) in CH₂Cl₂ (4 mL) to provide 223 mg (86%) of **14** as white crystals: mp 74–77 °C; TLC R_f 0.78 (EtOAc/toluene, 1:4); $[\alpha]_D^{26} - 45.6$ (c 1.02, CHCl₃); IR (neat) 2958, 2858, 1678, 1608 cm⁻¹; $^1\text{H-NMR}$ (500 MHz) δ 0.97 (s, 3H), 1.05 (s, 9H), 1.17 (s, 3H), 1.36–1.45 (m, 2H), 1.65–1.70 (m, 2H), 1.67 (s, 3H), 1.86–1.91 (m, 3H), 2.08 (dd, 1H, $J = 7.8, 13.8$ Hz), 2.13 (t, 2H, $J = 7.8$ Hz), 2.15 (m, 1H), 3.42 (d, 1H, $J = 13.8$ Hz), 3.48 (d, 1H, $J = 13.8$ Hz), 3.64 (t, 2H, $J = 6.3$ Hz), 3.91 (dd, 1H, $J = 4.9, 7.8$ Hz), 4.41 (d, 2H, $J = 7.1$ Hz), 5.35 (t, 1H, $J = 7.1$ Hz), 5.96 (d, 1H, $J = 12.0$ Hz), 7.36–7.44 (m, 6H), 7.65–7.67 (m, 4H), 7.70 (d, 1H, $J = 12.0$ Hz); $^{13}\text{C-NMR}$ (125 MHz) δ 16.6, 19.2, 19.9, 20.8, 26.5, 26.9 (3C), 30.5, 32.8, 35.7, 38.6, 44.7, 47.8, 48.2, 53.1, 63.3, 65.0, 68.1, 97.0, 117.6, 127.6 (4C), 129.5 (2C), 134.0 (2C), 135.6 (4C), 143.4, 163.4, 165.0; HRMS calcd for C₃₂H₄₀NO₅SSi (M⁺-*t*-C₄H₉) m/z 578.2396, found 578.2398.

(2*R*)-*N*-[(2*R*,3*S*)-6-(*tert*-Butyldiphenysilyloxy)-2-formyl-3-methyl-3-vinylhexanoyl]bornane-10,2-sultam (**15a**) and (2*R*)-*N*-[(2*S*,3*R*)]-Isomer (**15b**). As described for the preparation of **7a** and **7b** from **6**, a solution of **14** (209 mg, 329 μ mol) and BHT (3.6 mg, 16 μ mol) in toluene (17 mL) was heated at 140 °C for 71 h to provide 150 mg (72%) of **15a** and 32.1 mg (15%) of **15b**. Compound **15a** was obtained as a colorless oil: TLC R_f 0.59 (EtOAc/toluene, 1:5); $[\alpha]_D^{23} - 88.2$ (c 1.46, CHCl₃); IR (neat) 2961, 2859, 1731, 1686 cm⁻¹; $^1\text{H-NMR}$ (500 MHz) δ 0.95 (s, 3H), 1.14 (s, 9H), 1.11 (s, 3H), 1.23 (s, 3H), 1.35–1.40 (m, 2H), 1.48–1.54 (m, 2H), 1.74 (m, 1H), 1.83–1.91 (m, 4H), 2.07–2.13 (m, 2H), 3.43 (d, 1H, $J = 13.8$ Hz), 3.50 (d, 1H, $J = 13.8$ Hz), 3.60 (t, 2H, $J = 6.3$ Hz), 3.95 (dd, 1H, $J = 5.4, 7.5$ Hz), 4.01 (d, 1H, $J = 2.5$ Hz), 5.05 (d, 1H, $J = 17.5$ Hz), 5.19 (d, 1H, $J = 10.9$ Hz), 5.88 (dd, 1H, $J = 10.9, 17.5$ Hz), 7.35–7.43 (m, 6H), 7.63–7.65 (m, 4H), 9.60 (d, 1H, $J = 2.5$ Hz); $^{13}\text{C-NMR}$ (125 MHz) δ 19.2, 19.8, 19.9, 20.8, 26.4, 26.7, 26.8 (3C), 32.9, 34.5, 38.5, 44.7, 45.3, 47.7, 48.1, 53.2, 63.9, 65.4, 65.5, 115.3, 127.6 (4C), 129.5 (2C), 134.0 (2C), 135.6 (4C), 142.3, 167.4, 197.2; HRMS calcd for C₃₂H₄₀NO₅SSi (M⁺-*t*-C₄H₉) m/z 578.2396, found 578.2401. Compound **15b** was obtained as a colorless oil: TLC R_f 0.69 (EtOAc/toluene, 1:5); $[\alpha]_D^{24} + 6.7$ (c 1.50, CHCl₃); IR (neat) 2961, 2859, 1728, 1696 cm⁻¹; $^1\text{H-NMR}$ (500 MHz) δ 0.94 (s, 3H), 1.04 (s, 9H), 1.10 (s, 3H), 1.27 (s, 3H), 1.33–1.39 (m, 2H), 1.51 (m, 1H), 1.62 (m, 1H), 1.70 (m, 1H), 1.87–1.91 (m, 4H), 2.06 (dd, 1H, $J = 7.8, 14.0$ Hz), 2.26 (m, 1H), 3.41 (d, 1H, $J = 13.7$ Hz), 3.48 (d, 1H, $J = 13.7$ Hz), 3.61 (t, 2H, $J = 6.5$ Hz), 3.87 (dd, 1H, $J = 4.9, 7.8$ Hz), 4.20 (s, 1H), 5.09 (d, 1H, $J = 17.5$ Hz), 5.23 (d, 1H, $J = 10.7$ Hz), 5.96 (dd, 1H,

$J = 10.7, 17.5$ Hz), 7.36–7.43 (m, 6H), 7.64–7.66 (m, 4H), 9.59 (s, 1H); $^{13}\text{C-NMR}$ (125 MHz) δ 19.2, 19.5, 19.9, 20.4, 26.4, 26.7, 26.9 (3C), 32.8, 34.9, 38.2, 42.7, 44.5, 47.7, 48.2, 53.1, 64.0, 65.2, 65.3, 115.1, 127.6 (4C), 129.5 (2C), 134.0 (2C), 135.6 (4C), 143.4, 166.3, 197.7; HRMS calcd for $\text{C}_{32}\text{H}_{40}\text{NO}_5\text{SSi}$ ($\text{M}^+ - t\text{-C}_4\text{H}_9$) m/z 578.2396, found 578.2389.

(2*R*)-*N*-{(*E*)-3-[(2*E*)-5-(1,3-Dioxolan-2-yl)-3-methylpent-2-en-1-yl]oxy}acryloyl}bornane-10,2-sultam (**17**). As described for the preparation of **6**, compound **5** (171 mg, 640 μmol) and **16** (121 mg, 703 μmol) were treated with *n*-Bu₃P (24 μL , 97 μmol) in CH₂Cl₂ (6 mL) to provide 222 mg (79%) of **17** as a colorless oil: TLC R_f 0.67 (EtOAc/toluene, 1:3); $[\alpha]_D^{25}$ -59.7 (c 1.16, CHCl₃); IR (neat) 2958, 2885, 1677, 1609 cm^{-1} ; $^1\text{H-NMR}$ (500 MHz) δ 0.97 (s, 3H), 1.18 (s, 3H), 1.34–1.45 (m, 2H), 1.72 (s, 3H), 1.77–1.81 (m, 2H), 1.87–1.91 (m, 3H), 2.07 (dd, 1H, $J = 7.8, 13.9$ Hz), 2.14 (m, 1H), 2.18 (t, 2H, $J = 8.1$ Hz), 3.43 (d, 1H, $J = 13.8$ Hz), 3.48 (d, 1H, $J = 13.8$ Hz), 3.84–3.86 (m, 2H), 3.91 (dd, 1H, $J = 5.0, 7.8$ Hz), 3.95–3.98 (m, 2H), 4.45 (d, 2H, $J = 6.9$ Hz), 4.86 (t, 1H, $J = 4.7$ Hz), 5.41 (t, 1H, $J = 6.9$ Hz), 5.96 (d, 1H, $J = 12.1$ Hz), 7.69 (d, 1H, $J = 12.1$ Hz); $^{13}\text{C-NMR}$ (125 MHz) δ 16.7, 19.9, 20.8, 26.5, 31.8, 32.7, 33.6, 38.5, 44.6, 47.7, 48.2, 53.0, 64.9 (2C), 65.0, 68.0, 97.0, 104.0, 117.8, 142.7, 163.3, 164.9; HRMS calcd for $\text{C}_{22}\text{H}_{33}\text{NO}_6\text{S}$ (M^+) m/z 439.2029, found 439.2035.

(2*R*)-*N*-[(2*R*,3*S*)-5-(1,3-Dioxolan-2-yl)-2-formyl-3-methyl-3-vinylpentanoyl]bornane-10,2-sultam (**18a**) and (2*R*)-*N*-[(2*S*,3*R*)]-Isomer (**18b**). As described for the preparation of **7a** and **7b** from **6**, a solution of **17** (219 mg, 498 μmol) and BHT (5.5 mg, 25 μmol) in toluene (25 mL) was heated at 140 °C for 116 h to provide 159 mg (73%) of **18a** and 34.0 mg (16%) of **18b**. Compound **18a** was obtained as white crystals: mp 116–118 °C; TLC R_f 0.67 (EtOAc/toluene, 1:2); $[\alpha]_D^{21}$ -119 (c 1.34, CHCl₃); IR (neat) 2964, 2886, 1731, 1684 cm^{-1} ; $^1\text{H-NMR}$ (500 MHz) δ 0.98 (s, 3H), 1.16 (s, 3H), 1.24 (s, 3H), 1.34–1.43 (m, 2H), 1.53–1.63 (m, 2H), 1.81 (m, 1H), 1.88–1.96 (m, 4H), 2.11–2.12 (m, 2H), 3.44 (d, 1H, $J = 13.7$ Hz), 3.51 (d, 1H, $J = 13.7$ Hz), 3.80–3.83 (m, 2H), 3.91–3.94 (m, 2H), 3.96 (t, 1H, $J = 6.6$ Hz), 4.01 (d, 1H, $J = 2.3$ Hz), 4.81 (t, 1H, $J = 4.2$ Hz), 5.08 (d, 1H, $J = 17.5$ Hz), 5.22 (d, 1H, $J = 10.6$ Hz), 5.89 (dd, 1H, $J = 10.6, 17.5$ Hz), 9.62 (d, 1H, $J = 2.3$ Hz); $^{13}\text{C-NMR}$ (125 MHz) δ 19.7, 19.9, 20.8, 26.4, 28.0, 32.0, 33.0, 38.5, 44.8, 45.0, 47.7, 48.1, 53.2, 64.9 (2C), 65.4 (2C), 104.3, 115.6, 141.9, 167.4, 197.1; HRMS calcd for $\text{C}_{22}\text{H}_{33}\text{NO}_6\text{S}$ (M^+) m/z 439.2029, found 439.2036. Compound **18b** was obtained as a colorless oil: TLC R_f 0.75 (EtOAc/toluene, 1:2); $[\alpha]_D^{22}$ +10.4 (c 1.67, CHCl₃); IR (neat) 2962, 2885, 1728, 1697 cm^{-1} ; $^1\text{H-NMR}$ (500 MHz) δ 0.94 (s, 3H), 1.10 (s, 3H), 1.29 (s, 3H), 1.32–1.42 (m, 2H), 1.58–1.65 (m, 2H), 1.74 (m, 1H), 1.87–1.94 (m, 4H), 2.07 (dd, 1H, $J = 7.8, 13.8$ Hz), 2.26 (m, 1H), 3.43 (d, 1H, $J = 13.9$ Hz), 3.48 (d, 1H, $J = 13.9$ Hz), 3.81–3.85 (m, 2H), 3.90–3.95 (m, 3H), 4.21 (s, 1H), 4.82 (t, 1H, $J = 4.4$ Hz), 5.12 (d, 1H, $J = 17.5$ Hz), 5.26 (d, 1H, $J = 10.9$ Hz), 5.98 (dd, 1H, $J = 10.9, 17.5$ Hz), 9.61 (s, 1H); $^{13}\text{C-NMR}$ (125 MHz) δ 19.2, 19.9, 20.4, 26.4, 28.1, 32.6, 32.7, 38.1, 42.5, 44.5, 47.7, 48.2, 53.0, 64.9 (2C), 65.2 (2C), 104.4, 115.5, 143.0, 166.2, 197.5; HRMS calcd for $\text{C}_{22}\text{H}_{33}\text{NO}_6\text{S}$ (M^+) m/z 439.2029, found 439.2032.

(2*R*)-*N*-[(2*R*,3*S*)-2-(Acetoxymethyl)-3,7-dimethyl-3-vinyloct-6-enoyl]bornane-10,2-sultam (**19a**). To a cooled (0 °C) stirred solution of **7a** (158 mg, 375 μmol) in EtOH (4 mL) was added NaBH₄ (14.2 mg, 375 μmol). The mixture was stirred at 0 °C for 4 h, quenched with saturated aqueous NH₄Cl (1 mL), diluted with H₂O (20 mL), and extracted with CH₂Cl₂ (10 mL \times 3). The combined extracts were dried

and concentrated under reduced pressure to provide crude alcohol (152 mg), which was used in the next step without further purification.

To a cooled (0 °C) stirred solution of crude alcohol in CH₂Cl₂ (4 mL) were added Ac₂O (85 µL, 0.90 mmol), Et₃N (150 µL, 1.08 mmol), and DMAP (4.4 mg, 36 µmol). The mixture was stirred at room temperature for 2.5 h, diluted with CH₂Cl₂ (20 mL), and washed with H₂O (10 mL × 2). The combined aqueous layers were extracted with CH₂Cl₂ (30 mL). The combined organic layer and extract were dried and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel (EtOAc/hexane, 1:15) to provide 137 mg (78% for 2 steps) of **19a** as a colorless oil: TLC *R_f* 0.61 (EtOAc/hexane, 1:2); [α]_D²¹ −38.4 (*c* 1.46, CHCl₃); IR (neat) 2964, 2884, 1745, 1690 cm^{−1}; ¹H-NMR (500 MHz) δ 0.96 (s, 3H), 1.10 (s, 3H), 1.13 (s, 3H), 1.27–1.47 (m, 3H), 1.55 (br s, 3H), 1.64 (br s, 3H), 1.65 (m, 1H), 1.81–1.92 (m, 5H), 1.99 (s, 3H), 2.09–2.13 (m, 2H), 3.35 (m, 1H), 3.43 (d, 1H, *J* = 13.7 Hz), 3.50 (d, 1H, *J* = 13.7 Hz), 3.94 (t, 1H, *J* = 6.4 Hz), 4.22 (t, 1H, *J* = 10.6 Hz), 4.37 (dd, 1H, *J* = 3.4, 10.6 Hz), 5.01 (m, 1H), 5.01 (d, 1H, *J* = 17.5 Hz), 5.16 (d, 1H, *J* = 10.9 Hz), 5.79 (dd, 1H, *J* = 10.9, 17.5 Hz); ¹³C-NMR (125 MHz) δ 17.5, 17.8, 20.0, 20.4, 20.9, 22.3, 25.6, 26.5, 32.9, 38.6, 38.7, 43.3, 44.5, 47.7 (2C), 52.2, 53.3, 63.0, 65.6, 114.5, 124.1, 131.5, 143.3, 171.0, 172.7; HRMS calcd for C₂₅H₃₉NO₅S (M⁺) *m/z* 465.2549, found 465.2556.

(2*R*)-*N*-[(2*S*,3*R*)-2-(Acetoxymethyl)-3,7-dimethyl-3-vinyloct-6-enoyl]bornane-10,2-sultam (**19b**). As described for the preparation of **19a** from **7a**, compound **7b** (33.7 mg, 79.9 µmol) was treated with NaBH₄ (1.5 mg, 40 µmol) in EtOH (1 mL) to provide crude alcohol (37.0 mg), which was then treated with Ac₂O (19 µL, 0.20 mmol), Et₃N (33 µL, 0.24 mmol), and DMAP (1.1 mg, 9.0 µmol) in CH₂Cl₂ (1 mL) to provide 24.2 mg (65% for 2 steps) of **19b** as a colorless oil: TLC *R_f* 0.68 (EtOAc/hexane, 1:2); [α]_D²⁰ −54.7 (*c* 1.06, CHCl₃); IR (neat) 2966, 2886, 1742, 1687 cm^{−1}; ¹H-NMR (500 MHz) δ 0.97 (s, 3H), 1.18 (s, 3H), 1.19 (s, 3H), 1.35–1.48 (m, 3H), 1.57 (br s, 3H), 1.61 (m, 1H), 1.65 (br s, 3H), 1.86–1.93 (m, 5H), 1.95 (s, 3H), 2.10 (dd, 1H, *J* = 7.8, 13.8 Hz), 2.19 (m, 1H), 3.26 (dd, 1H, *J* = 3.7, 10.6 Hz), 3.47 (d, 1H, *J* = 13.8 Hz), 3.52 (d, 1H, *J* = 13.8 Hz), 3.94 (dd, 1H, *J* = 5.2, 7.8 Hz), 4.06 (t, 1H, *J* = 10.6 Hz), 4.56 (dd, 1H, *J* = 3.7, 10.6 Hz), 5.02 (d, 1H, *J* = 17.4 Hz), 5.06 (m, 1H), 5.16 (d, 1H, *J* = 11.3 Hz), 5.84 (dd, 1H, *J* = 11.3, 17.4 Hz); ¹³C-NMR (125 MHz) δ 17.6, 18.6, 19.9, 20.8, 21.1, 22.5, 25.7, 26.3, 33.0, 37.9, 38.6, 42.4, 44.6, 47.7, 47.8, 52.0, 53.3, 64.6, 65.8, 114.2, 124.5, 131.2, 143.9, 170.6, 172.6; HRMS calcd for C₂₅H₃₉NO₅S (M⁺) *m/z* 465.2549, found 465.2558.

(2*R*)-*N*-[(2*R*,3*S*)-2-(Acetoxymethyl)-6-(*tert*-butyldiphenylsilyloxy)-3-methyl-3-vinylhexanoyl]bornane-10,2-sultam (**20a**). As described for the preparation of **19a** from **7a**, compound **15a** (150 mg, 236 µmol) was treated with NaBH₄ (4.4 mg, 0.12 mmol) in EtOH (3 mL) to provide crude alcohol (152 mg), which was then treated with Ac₂O (56 µL, 0.59 mmol), Et₃N (99 µL, 0.71 mmol), and DMAP (3.0 mg, 25 µmol) in CH₂Cl₂ (3 mL) to provide 151 mg (94% for 2 steps) of **20a** as a colorless oil: TLC *R_f* 0.66 (EtOAc/toluene, 1:5); [α]_D²³ −28.6 (*c* 2.01, CHCl₃); IR (neat) 2960, 2859, 1744, 1691 cm^{−1}; ¹H-NMR (500 MHz) δ 0.92 (s, 3H), 1.03 (s, 9H), 1.03 (s, 3H), 1.07 (s, 3H), 1.32–1.46 (m, 5H), 1.72 (m, 1H), 1.80 (m, 1H), 1.88–1.90 (m, 2H), 1.98 (s, 3H), 2.06–2.09 (m, 2H), 3.34 (m, 1H), 3.41 (d, 1H, *J* = 13.8 Hz), 3.47 (d, 1H, *J* = 13.8 Hz), 3.54–3.60 (m, 2H), 3.92 (t, 1H, *J* = 6.3 Hz), 4.22 (t, 1H, *J* = 10.6 Hz), 4.36 (dd, 1H, *J* = 3.4, 10.6 Hz), 4.99 (d, 1H, *J* = 17.5 Hz), 5.13 (d, 1H, *J* = 11.0 Hz), 5.75 (dd, 1H, *J* = 11.0, 17.5 Hz), 7.35–7.43 (m, 6H), 7.63–7.64 (m, 4H); ¹³C-NMR (125 MHz) δ 18.2, 19.1,

19.9, 20.5, 20.9, 26.5, 26.8 (3C), 27.0, 32.9, 34.4, 38.6, 43.0, 44.4, 47.6 (2C), 52.2, 53.3, 63.0, 64.1, 65.6, 114.6, 127.6 (4C), 129.5 (2C), 133.9, 134.0, 135.5 (2C), 135.6 (2C), 143.2, 171.0, 172.6; HRMS calcd for $C_{34}H_{44}NO_6SSi$ ($M^+ - t-C_4H_9$) m/z 622.2659, found 622.2677.

Synthesis of 19a from 20a. To a cooled (0 °C) stirred solution of **20a** (12.2 mg, 17.9 μ mol) in THF (3 mL) was added HF·pyridine (0.2 mL). The mixture was stirred at room temperature for 5 h and quenched with saturated aqueous $NaHCO_3$ (1 mL). This was diluted with H_2O (15 mL) and extracted with CH_2Cl_2 (10 mL \times 4). The combined extracts were dried and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel (EtOAc/hexane, 1:2) to provide 8.0 mg (quant.) of alcohol as white crystals: mp 113–115 °C; TLC R_f 0.24 (EtOAc/hexane, 1:2); $[\alpha]_D^{20}$ -42.7 (c 1.02, $CHCl_3$); IR (neat) 3529, 2961, 2882, 1741, 1690 cm^{-1} ; 1H -NMR (500 MHz) δ 0.97 (s, 3H), 1.09 (s, 3H), 1.16 (s, 3H), 1.35–1.58 (m, 5H), 1.67 (m, 1H), 1.88–1.92 (m, 3H), 1.99 (s, 3H), 2.09–2.15 (m, 2H), 3.37 (m, 1H), 3.44 (d, 1H, $J = 13.9$ Hz), 3.50 (d, 1H, $J = 13.9$ Hz), 3.54 (m, 1H), 3.61 (m, 1H), 3.95 (t, 1H, $J = 6.5$ Hz), 4.20 (t, 1H, $J = 10.7$ Hz), 4.40 (dd, 1H, $J = 3.4, 10.7$ Hz), 5.02 (d, 1H, $J = 17.5$ Hz), 5.15 (d, 1H, $J = 11.3$ Hz), 5.80 (dd, 1H, $J = 11.3, 17.5$ Hz); ^{13}C -NMR (125 MHz) δ 18.7, 19.9, 20.5, 20.9, 26.5, 27.1, 32.9, 34.4, 38.6, 42.9, 44.5, 47.7 (2C), 51.8, 53.3, 63.0, 63.1, 65.7, 114.5, 143.1, 171.2, 172.6; HRMS calcd for $C_{22}H_{35}NO_6S$ (M^+) m/z 441.2185, found 441.2192.

To a cooled (0 °C) stirred solution of alcohol (20.9 mg, 47.3 μ mol) in CH_2Cl_2 (1 mL) was added Dess–Martin periodinane (30.3 mg, 71.4 μ mol). The mixture was stirred at room temperature for 2 h and Dess–Martin periodinane (31.1 mg, 73.3 μ mol) was added. After being stirred at room temperature for 2.5 h, the mixture was quenched with saturated aqueous $Na_2S_2O_3$ (3 mL) and saturated aqueous $NaHCO_3$ (3 mL), diluted with H_2O (4 mL), and extracted with CH_2Cl_2 (15 mL \times 3). The combined extracts were washed with saturated brine (20 mL), dried and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel (EtOAc/hexane, 1:7) to provide 20.8 mg (quant.) of aldehyde as a colorless oil, which was immediately used in the next step: TLC R_f 0.33 (EtOAc/hexane, 1:2); 1H -NMR (300 MHz) δ 0.97 (s, 3H), 1.07 (s, 3H), 1.17 (s, 3H), 1.33–1.48 (m, 4H), 1.68 (m, 1H), 1.89–2.04 (m, 2H), 1.99 (s, 3H), 2.11–2.13 (m, 2H), 2.41 (t, 2H, $J = 7.8$ Hz), 3.38 (m, 1H), 3.44 (d, 1H, $J = 13.9$ Hz), 3.52 (d, 1H, $J = 13.9$ Hz), 3.95 (t, 1H, $J = 6.5$ Hz), 4.21 (t, 1H, $J = 10.7$ Hz), 4.37 (dd, 1H, $J = 3.6, 10.7$ Hz), 5.05 (d, 1H, $J = 17.5$ Hz), 5.20 (d, 1H, $J = 10.7$ Hz), 5.78 (dd, 1H, $J = 10.7, 17.5$ Hz), 9.73 (s, 1H).

The following reaction was carried out under Ar. To a cooled (0 °C) stirred suspension of i -PrP $^+Ph_3I^-$ (21.9 mg, 49.1 μ mol) in THF (1 mL) was added t -BuLi (1.61 M solution in pentane, 29 μ L, 47 μ mol). The mixture was stirred at 0 °C for 30 min and a solution of aldehyde (6.9 mg, 16 μ mol) in THF (1 mL) was added. After being stirred at 0 °C for 20 min, the mixture was diluted with H_2O (10 mL) and extracted with CH_2Cl_2 (15 mL \times 3). The combined extracts were dried and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel (EtOAc/hexane, 1:15) to provide 3.3 mg (45%) of **19a**.

(2R)-N-[(2R,3S)-2-(Acetoxymethyl)-5-(1,3-dioxolan-2-yl)-3-methyl-3-vinylpentanoyl]bornane-10,2-sultam (**21a**). As described for the preparation of **19a** from **7a**, compound **18a** (154 mg, 350 μ mol) was treated with $NaBH_4$ (6.5 mg, 0.17 mmol) in EtOH (3 mL) to provide crude alcohol (158 mg), which was then treated with Ac_2O (83 μ L, 0.88 mmol), Et_3N (146 μ L, 1.05 mmol), and DMAP (4.4 mg, 36 μ mol)

in CH₂Cl₂ (4 mL) to provide 150 mg (88% for 2 steps) of **21a** as a colorless oil: TLC *R_f* 0.65 (EtOAc/toluene, 1:2); [α]_D²¹−39.5 (*c* 1.02, CHCl₃); IR (neat) 2962, 2884, 1743, 1690 cm^{−1}; ¹H-NMR (500 MHz) δ 0.97 (s, 3H), 1.08 (s, 3H), 1.16 (s, 3H), 1.36 (m, 1H), 1.43–1.50 (m, 2H), 1.55–1.60 (m, 2H), 1.78 (m, 1H), 1.87–1.91 (m, 3H), 1.99 (s, 3H), 2.11–2.18 (m, 2H), 3.35 (m, 1H), 3.43 (d, 1H, *J* = 13.7 Hz), 3.50 (d, 1H, *J* = 13.7 Hz), 3.78–3.81 (m, 2H), 3.91–3.95 (m, 3H), 4.22 (t, 1H, *J* = 10.7 Hz), 4.38 (dd, 1H, *J* = 3.5, 10.7 Hz), 4.76 (t, 1H, *J* = 4.6 Hz), 5.01 (d, 1H, *J* = 17.5 Hz), 5.17 (d, 1H, *J* = 10.7 Hz), 5.77 (dd, 1H, *J* = 10.7, 17.5 Hz); ¹³C-NMR (125 MHz) δ 18.1, 20.0, 20.5, 20.9, 26.5, 28.3, 32.3, 32.9, 38.6, 42.8, 44.5, 47.7 (2C), 52.2, 53.3, 63.0, 64.7, 64.8, 65.6, 104.5, 114.9, 142.9, 171.0, 172.5; HRMS calcd for C₂₄H₃₇NO₇S (M⁺) *m/z* 483.2291, found 483.2291.

Synthesis of 19a from 21a. A solution of **21a** (80.5 mg, 166 μ mol) in THF (12 mL) and 4 M aqueous HCl (12 mL) was stirred at 0 °C for 15 h, diluted with saturated aqueous NaHCO₃ (50 mL), and extracted with CH₂Cl₂ (60 mL \times 3). The combined extracts were dried and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel (EtOAc/hexane, 1:7) to provide 58.2 mg (80%) of aldehyde, which was identical with the aldehyde derived from **20a** and converted into **19a** as described above.

4. Conclusions

In conclusion, we have developed an asymmetric Claisen rearrangement using Oppolzer's camphorsultam as a chiral auxiliary. Notably, rearrangement products **7a**, **15a**, and **18a** possess a chiral quaternary carbon with high enantiomeric purity. In addition, this method has been applied to the total synthesis of (+)-bakuchiol (**4**). Further studies and applications of this work to natural product synthesis are in progress and will be reported in due course.

References

1. Corey, E.J.; Guzman-Perez, A. The catalytic enantioselective construction of molecules with quaternary carbon stereocenters. *Angew. Chem. Int. Ed.* **1998**, *37*, 388–401.
2. Denissova, I.; Barriault, L. Stereoselective formation of quaternary carbon centers and related functions. *Tetrahedron* **2003**, *59*, 10105–10146.
3. Trost, B.M.; Jiang, C. Catalytic enantioselective construction of all-carbon quaternary stereocenters. *Synthesis* **2006**, 369–396.
4. Bystrov, N.S.; Chernov, B.K.; Dobrynin, V.N.; Kolosov, M.N. The structure of hyperforin. *Tetrahedron Lett.* **1975**, *16*, 2791–2794.
5. Wu, J.; Cheng, X.-F.; Harrison, L.J.; Goh, S.-H.; Sim, K.-Y. A phloroglucinol derivative with a new carbon skeleton from *Hypericum perforatum* (Guttiferae). *Tetrahedron Lett.* **2004**, *45*, 9657–9659.
6. Takao, K.; Kojima, Y.; Miyashita, T.; Yashiro, K.; Yamada, T.; Tadano, K. Enantioselective synthesis of a 3,5,5-trialkylated tetronic acid derivative. *Heterocycles* **2009**, *77*, 167–172.
7. Kawazu, K. Isolation of vibsanins A, B, C, D, E and F from *Viburnum odoratissimum*. *Agric. Biol. Chem.* **1980**, *44*, 1367–1372.
8. Mehta, G.; Nayak, U.R.; Dev, S. Bakuchiol, A novel monoterpenoid. *Tetrahedron Lett.* **1966**, *7*, 4561–4567.

9. Takano, S.; Shimazaki, Y.; Ogasawara, K. Enantiocontrolled synthesis of natural (+)-bakuchiol. *Tetrahedron Lett.* **1990**, *31*, 3325–3326.
10. Du, X.-L.; Chen, H.-L.; Feng, H.-J.; Li, Y.-C. Stereoselective total synthesis of natural (*S*)-bakuchiol and its enantiomer. *Helv. Chim. Acta* **2008**, *91*, 371–378.
11. Esumi, T.; Shimizu, H.; Kashiya, A.; Sasaki, C.; Toyota, M.; Fukuyama, Y. Efficient construction of a chiral all-carbon quaternary center by asymmetric 1,4-addition and its application to total synthesis of (+)-bakuchiol. *Tetrahedron Lett.* **2008**, *49*, 6846–6849.
12. Bequette, J.P.; Jungong, C.S.; Novikov, A.V. Enantioselective synthesis of bakuchiol using diazosulfonate C–H insertion to install the quaternary center. *Tetrahedron Lett.* **2009**, *50*, 6963–6964.
13. Gao, F.; McGrath, K.P.; Lee, Y.; Hoveyda, A.H. Synthesis of quaternary carbon stereogenic centers through enantioselective Cu-catalyzed allylic substitutions with vinylaluminum reagents. *J. Am. Chem. Soc.* **2010**, *132*, 14315–14320.
14. Ito, H.; Taguchi, T. Asymmetric Claisen rearrangement. *Chem. Soc. Rev.* **1999**, *28*, 43–50.
15. Martín Castro, A.M. Claisen rearrangement over the past nine decades. *Chem. Rev.* **2004**, *104*, 2939–3002.
16. Takao, K.; Hayakawa, N.; Yamada, R.; Yamaguchi, T.; Morita, U.; Kawasaki, S.; Tadano, K. Total synthesis of (–)-pestalotiopsin A. *Angew. Chem. Int. Ed.* **2008**, *47*, 3426–3429.
17. Takao, K.; Hayakawa, N.; Yamada, R.; Yamaguchi, T.; Saegusa, H.; Uchida, M.; Samejima, S.; Tadano, K. Total syntheses of (+)- and (–)-pestalotiopsin A. *J. Org. Chem.* **2009**, *74*, 6452–6461.
18. Fonquerna, S.; Moyano, A.; Pericàs, M.A.; Riera, A. A convenient preparation of *N*-(2-alkynoyl) derivatives of chiral oxazolidin-2-ones and bornane-10,2-sultam. *Tetrahedron: Asymmetry* **1997**, *8*, 1685–1691.
19. Inanaga, J.; Baba, Y.; Hanamoto, T. Organic synthesis with trialkylphosphine catalysts. Conjugate addition of alcohols to α,β -unsaturated alkynic acid esters. *Chem. Lett.* **1993**, *22*, 241–244.
20. In contrast, the use of Evans' oxazolidinone (4-benzyl-2-oxazolidinone) as the chiral auxiliary for the Claisen rearrangement gave no stereoselectivity (dr = 1.2:1).
21. Chen, H.; Du, X.; Tang, W.; Zhou, Y.; Zuo, J.; Feng, H.; Li, Y. Synthesis and structure-immunosuppressive activity relationships of bakuchiol and its derivatives. *Bioorg. Med. Chem.* **2008**, *16*, 2403–2411.
22. Carnduff, J.; Miller, J.A. The synthesis of (\pm)-bakuchiol. *J. Chem. Soc. C* **1968**, 2671–2673.
23. Kim, G.T.; Wenz, M.; Park, J.I.; Hasserodt, J.; Janda, K.D. Polyene substrates with unusual methylation patterns to probe the active sites of three catalytic antibodies. *Bioorg. Med. Chem.* **2002**, *10*, 1249–1262.
24. Oppolzer, W.; Poli, G.; Starkemann, C.; Bernardinelli, G. Stable and reactive conformations of *N*-enoyl-bornane-10,2-sultams in the absence of Lewis acids: Asymmetric 1,4-hydride additions. *Tetrahedron Lett.* **1988**, *29*, 3559–3562.

Sample Availability: Not available.